Multiple Myeloma (MM) Recruiting Phase 2 Trials for Fludarabine (DB01073)

Back to Multiple Myeloma (MM)

Also known as: MULTIPLE MYELOMA (MM) / Multiple myeloma / Myeloma, Multiple / Multiple Myelomas / Multiple Myeloma(MM) / Plasma cell myelomas / Myelomatosis multiple / Peripheral plasma cell myeloma / Myelomatosis / Multiple myeloma myelomatosis / Plasma cell myeloma / Myeloma / Multiple myeloma with failed remission

Indication	Status	Phase
DBCOND0040908 (Multiple Myeloma (MM))	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01119066	HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies	Treatment	Busulfan (DB01008) Clofarabine (DB00631) Cyclophosphamide (DB00531) Fludarabine (DB01073) Melphalan (DB01042) Thiotepa (DB04572)
NCT02661035	Allo HSCT Using RIC for Hematological Diseases	Treatment	Allopurinol (DB00437) Cyclophosphamide (DB00531) Fludarabine (DB01073) Mycophenolate mofetil (DB00688) Tacrolimus (DB00864)
NCT02722668	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	Treatment	Cyclophosphamide (DB00531) Fludarabine (DB01073) Mycophenolate mofetil (DB00688) Sirolimus (DB00877)
NCT03159702	Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation	Treatment	Fludarabine (DB01073) Melphalan (DB01042)
NCT02581007	RIC Transplant Using Haplo Donors	Treatment	Cyclophosphamide (DB00531) Fludarabine (DB01073) Melphalan (DB01042)
NCT02861417	Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation	Treatment	Busulfan (DB01008) Coenzyme M (DB09110) Cyclophosphamide (DB00531) Filgrastim (DB00099) Fludarabine (DB01073) Mycophenolate mofetil (DB00688) Tacrolimus (DB00864) Thiotepa (DB04572)